Supporters of Janet Woodcock’s bid to become commissioner of the US Food and Drug Administration are emerging, although one of the biggest is choosing to stay in the background.
Dozens of rare disease and other patient organizations have penned letters supporting Woodcock, who currently is the acting FDA commissioner. And Friends of Cancer Research Chair and Founder Ellen Sigal was one of the co-authors of an
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?